Abstract:BACKGROUND:During the transfusion of blood components, the transfer of allogeneic donor white blood cells (WBCs) can mediate transfusion-associated graft-versus-host disease (TA-GVHD). To minimize the reaction, exposure of blood products to gamma irradiation is currently the standard of care. The aim of our study was to evaluate and compare hemostatic function, transfusion efficacy, and safety of gamma-irradiated single-donor apheresis platelet concentrates (PCs) and of conventional non-irradiated PCs in patients with chemotherapy-induced thrombocytopenia. METHODS:20 double-dose single-donor leukoreduced PCs were split in two identical units; one was gamma-irradiated with 25 Gy (study arm A) and the other remains non-irradiated (study arm B). Both units were stored under equal conditions. Hematologic patients were randomly assigned to receive gamma-irradiated or conventional non-irradiated PCs. Hemostatic function was evaluated by thrombelastography (TEG). TEG measurements were taken pre transfusion and 1 and 24 h post transfusion. TEG profiles were measured, noting the time to initiate clotting (R), the angle of clot formation (α), and the maximum amplitude (clot strength (MA)). Whole blood samples were collected from these thrombocytopenic patients at 1 and 24 h for PLT count increments (CIs) and corrected count increments (CCIs) with assessments of transfusion efficacy. Time to next PLT transfusion, transfusion requirement of RBCs, active bleeding, and adverse events (AEs), were analyzed. RESULTS:No differences could be found in hemostatic function parameters (MA, R, and α) between study arms A and B (all p values > 0.096) pre transfusion as well as 1 and 24 h post transfusion. No differences between study arms A and B were observed for mean (± standard deviation (SD)) 1-hour CCI (12.83 ± 6.33 vs. 11.59 ± 5.97) and 24-hour CCI (6.56 ± 4.10 vs. 5.76 ± 4.05). Mean 1-hour CI and 24-hour CI were not significantly different in both study arms (p = 0.254 and p = 0.242 respectively). Median time to the next PC transfusion after study PC was not significantly different between groups: (2.4 vs. 2.2 days, p = 0.767). No differences could be found in transfusion requirement of red blood cells (p = 0.744) between both study arms. There were also no regarding bleeding, adverse events, and acute transfusion reaction(s). CONCLUSIONS:This study confirms safety of gamma-irradiated PCs for treatment thrombocytopenia. Hemostatic function, transfusion efficacy, bleeding, and safety of single-donor apheresis PCs treated with gamma irradiation versus untreated control PCs are comparable.

Comparison Between the Clinical Efficacy of Platelet Concentrates, Derived from Buffy Coat and Apheresis in Tumor Patients.

Comparison of Therapeutic Effect of Apheresis Platelets and Buffy Coat-Derived Platelet Concentrates

Comparative analysis of the quality of platelet concentrates produced by apheresis procedures, platelet rich plasma, and buffy coat

Qualities and Curative Effects of Single Donor Platelets and Buffy-coat-collected Platelets Concentrates

Building And Clinical Use Of Activated Plasma Clotting Time Test And The Value Of Apct On Predicting The Bleeding Due To Leukemia Chemotherapy-Induced Thrombocytopenia

Hemostatic function and transfusion efficacy of apheresis platelet concentrates treated with gamma irradiation in use for thrombocytopenic patients.

Quality assessment of platelet concentrates prepared by platelet-rich plasma, buffy-coat, and apheresis methods in a tertiary care hospital in South India: A cross-sectional study

Analysis of Efficacy of Apheresis Platelets Transfusion on Patients with Haematological Diseases

Improving platelet function following prophylactic platelet transfusion in patients with hematological malignancies

Platelet closure time in the evaluation of efficacy of CAR-T cell therapy in relapsed/refractory multiple myeloma

Correlation between the extent of platelet activation in platelet concentrates and in vitro and in vivo parameters

Improvement of Plateletpheresis Via Technical Modification on the MCS+

Hematopoietic Progenitor Cell Counting for Prediction of the Yield of Peripheral Blood Stem Cell in Mobilization and Harvest

[Effect of Artificial Liver with Double Plasma Molecular Absorb System Model on Patients' Platelets and Corresponding Treatment Strategy].

Sample preparation technique and white cell content influence the detectable levels of growth factors in platelet concentrates

The effect of agitating buffy coats on platelet quality before soft spin

Correlation analysis between platelet parameters and efficacy of platelet transfusion and prognosis

Differences between first‐ and second‐generation autologous platelet concentrates

Clinical efficacy of platelet transfusion therapy in patients with leukemia and analysis of risk factors for ineffective transfusion

Clinical Utility of Automated Platelet Clump Count in the Screening for Ethylene Diamine Tetraacetic Acid-Dependent Pseudothrombocytopenia.

Clinical Study of a Novel Platelet Dumps Count in Differentiating True Thrombocytopenia from Pseudothrombocytopenia